Navigation Links
Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
Date:12/15/2011

PRINCETON, N.J., Dec. 15, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. Initial development work will be covered pursuant to a previously issued $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant enabling development of thermo-stable ricin and anthrax vaccines.

The option encompasses an issued U.S. patent that covers engineered variants of protective antigen (PA) developed in the Harvard Medical School laboratory of Dr. John Collier.  PA is the principal determinant of protective immunity to anthrax. Soligenix believes that it will be able to develop the Collier anthrax vaccine with an efficacy profile superior to other anthrax vaccines.

There has been a major effort on the part of the federal government to develop improved vaccines for use both pre- and post anthrax exposure. The vaccine currently in use, known as AVA (anthrax vaccine adsorbed), consists of a defined, but impure, mixture of bacterial components. AVA is FDA approved, but requires multiple injections followed by annual boosters. Vaccines such as AVA or others based on purified, native recombinant PA (rPA) sequences induce antibodies that neutralize anthrax holotoxin and can strongly protect animals from inhaled anthrax spores.  To date, the government has funded more than $4 billion in anthrax vaccine development and commercial contracts.

"We are pleased to secure from Harvard option rights under the patent that covers this promising anthrax vaccine and to initiate its development under our existing grant funding," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "We b
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Reports Third Quarter 2011 Financial Results
2. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
3. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
4. Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
5. Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
6. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
7. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
8. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
9. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
10. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... 30, 2015 First Choice Wellness Care recently ... Duality and is the only clinic in the greater ... removal treatments. The practice has recently expanded their services ... to showcase their focus in the procedure. They upgraded ... faster ink clearance, and superior service. "We,ve ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:6/30/2015)... ... June 30, 2015 , ... After more than ... Food and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin ... rating of 35, hits the market just in time to help protect the skin ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... drug response profiling test to help oncologists provide personalized cancer treatment, will ... CorrectChemo® assay provides the oncologist with valuable insight on how a specific ...
(Date:6/30/2015)... Vancouver, BC (PRWEB) , ... June 30, 2015 ... ... authority in medical device market research, has launched a new reimbursement insurance policy ... and healthcare professionals to receive US insurance policy and rate updates in real-time ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... The company provides high quality record management services for patient records. Medical imaging ... normally required by physicians and clinics. , With the increase in the ...
(Date:6/30/2015)... ... June 30, 2015 , ... The Citizens Commission ... Davis (D-IL) for writing to the Department of Health and Human Services (HHS), ... healthcare system, Universal Health Services (UHS).[1] CCHR is expanding its seven-year review of ...
Breaking Medicine News(10 mins):Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Micro Com Systems Ltd Now Specializes in Medical Imaging 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5
... This press release is available in French . ... older who are in overall good health are perfectly able ... Dr. Kevin Lachapelle of the McGill University Health Centre (MUHC). ... 2008 Canadian Cardiovascular Congress. , "Age should not be a ...
... Foundation,s Online Report Card Provides,Information on NY, NJ, ... Payments, LAKE SUCCESS, N.Y., Oct. 28 ... have a unique tool for,evaluating the region,s hospitals ... Accountability Foundation,s Regional Health Care Report Card.,The report ...
... popular licensed characters will add significant growth to the ... ... Derma Sciences, Inc.,(OTC Bulletin Board: DSCI) announced today that it ... for use within the highly popular and growing segment of ...
... in "A Strategy of Home Telehealth for the Management of ... ... Minneapolis (PRWEB) October 28, 2008 -- American TeleCare, Inc. (ATI), ... and video-based telehealth solutions, announced that its InLife™ and LifeView™ ...
... at American Society of Plastic Surgeons Annual Meeting, ... Bel Air resident, a burn victim from an accident ... people of special needs,will be the proud recipient of ... the American Society of Plastic Surgeons (ASPS) Plastic,Surgery 2008 ...
... Oct. 28 As Americans curtail spending to,offset ... small business that,s proven to provide an invaluable ... - a franchised stroller,exercise program for new moms ... "I,m definitely not losing clients," explains Rachel Pustilnik, ...
Cached Medicine News:Health News:Foundation Releases Comprehensive Regional Health Care Report Card 2Health News:Foundation Releases Comprehensive Regional Health Care Report Card 3Health News:Foundation Releases Comprehensive Regional Health Care Report Card 4Health News:Derma Sciences Announces 3-Year Licensing Deals for Highly Profitable Character Strip Bandages 2Health News:Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada 2Health News:Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada 3Health News:Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada 4Health News:Baltimore Local, Burn Victim Wins Patient of Courage Award 2Health News:Stroller Strides(R) Franchises Succeed Despite Economic Climate 2
Shandon Microscope Slide Cabinet with Drawers...
... data from multiple sources is not ... ResultNet/Plus software allows you to concentrate ... communications network., ,ResultNet/Plus eliminates the complexity ... largescale or multi-site laboratories to host ...
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
ACE Control Serum provides the laboratory with vital information on the performance of the ACE chemistry assay....
Medicine Products: